Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06104228 · ClinicalTrials.gov registry record · Phase 2
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
A Phase 2 study of Pulmonary Arterial Hypertension and Connective Tissue Diseases, sponsored by Bastiaan Driehuys.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06104228 is a Phase 2 study of Pulmonary Arterial Hypertension and Connective Tissue Diseases that is actively recruiting participants, run by Bastiaan Driehuys. The registered enrollment target is 20 participants, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06104228, a Phase 2 study of Pulmonary Arterial Hypertension and Connective Tissue Diseases, is actively recruiting participants, sponsored by Bastiaan Driehuys.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall study objectives outlined in this study are to derive 129Xe MRI pulmonary vascular biomarker signatures that differentiate common subtypes of PAH and to determine the ability of 129Xe MRI to longitudinally monitor disease progression and response to therapy in PAH, with the aid of additional assessments, such as labs, echocardiography, and six-minute walk distance (6MWD).
Conditions Studied
Interventions
- DRUG 129Xe Hyperpolarized
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-08-12 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06104228
The ClinicalTrials.gov registry entry for NCT06104228 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (96% lower). The listed sponsor is Bastiaan Driehuys, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 1 intervention - of which 129Xe Hyperpolarized is the first listed.
NCT06104228 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06104228 about?
NCT06104228 is a clinical study titled "129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)". The overall study objectives outlined in this study are to derive 129Xe MRI pulmonary vascular biomarker signatures that differentiate common subtypes of PAH and to determine the ability of 129Xe MRI to longitudinally monitor disease progression and response to therapy in PAH, with the aid of additi...
What is the current status of trial NCT06104228?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-08-12. Estimated completion is 2027-03-31.
What conditions does trial NCT06104228 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension, Connective Tissue Diseases, Idiopathic Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder).
What interventions are being tested in trial NCT06104228?
The interventions under investigation include: 129Xe Hyperpolarized (DRUG).
Who is sponsoring clinical trial NCT06104228?
This trial is sponsored by Bastiaan Driehuys, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06104228 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
-
Xenon MRI Pulm Hypertension
RECRUITING · Phase 2
-
Repurposing Valsartan May Protect Against Pulmonary Hypertension
RECRUITING · Phase 2
-
Spironolactone for Pulmonary Arterial Hypertension
RECRUITING · Phase 2
-
129 Xenon Imaging in Patients Treated With Sotatercept
RECRUITING · Phase 2
-
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
RECRUITING · Phase 2
Explore more on PlainTrial
Pulmonary Arterial Hypertension
All registered trials for this condition
Connective Tissue Diseases
All registered trials for this condition
North Carolina
All trials with a study site in North Carolina
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.